NASDAQ:CRSPCrispr Therapeutics Stock Price, Forecast & News

Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRSP shares have increased by 43.9% and is now trading at $62.26. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics.

Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Crispr Therapeutics.

Crispr Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Tuesday, April, 28th. The company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.10. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $3.04 million. Crispr Therapeutics had a net margin of 15.73% and a return on equity of 6.54%. The business's revenue was down 52.1% compared to the same quarter last year. During the same period last year, the business posted ($0.93) EPS. View Crispr Therapeutics' earnings history.

15 equities research analysts have issued 12-month price targets for Crispr Therapeutics' shares. Their forecasts range from $31.00 to $104.00. On average, they expect Crispr Therapeutics' stock price to reach $74.42 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts' price targets for Crispr Therapeutics.

News coverage about CRSP stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Crispr Therapeutics earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutCrispr Therapeutics.

Crispr Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,020,000 shares, an increase of 11.7% from the April 30th total of 3,600,000 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is currently 4.0 days. Currently, 8.5% of the company's shares are sold short. View Crispr Therapeutics' Current Options Chain.

Some companies that are related to Crispr Therapeutics include Neurocrine Biosciences (NBIX), BioNTech (BNTX), argenx (ARGX), Qiagen (QGEN), BIO-TECHNE (TECH), Repligen (RGEN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE) and Momenta Pharmaceuticals (MNTA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intellia Therapeutics (NTLA), Canopy Growth (CGC), Square (SQ), Vertex Pharmaceuticals (VRTX) and Intel (INTC).

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Crispr Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (6.17%), Federated Hermes Inc. (1.77%), Morgan Stanley (1.40%), Morgan Stanley (1.40%), Wellington Management Group LLP (1.16%) and Cormorant Asset Management LP (1.03%). Company insiders that own Crispr Therapeutics stock include Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Vertex Pharmaceuticals (Europe. View institutional ownership trends for Crispr Therapeutics.

CRSP stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Two Sigma Investments LP, Orbimed Advisors LLC, Federated Hermes Inc., Deutsche Bank AG, Two Sigma Advisers LP, JPMorgan Chase & Co., and Squarepoint Ops LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, and Samarth Kulkarni. View insider buying and selling activity for Crispr Therapeutics.

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Morgan Stanley, Morgan Stanley, TimesSquare Capital Management LLC, Casdin Capital LLC, Capital International Investors, Bank of New York Mellon Corp, and Acadian Asset Management LLC. View insider buying and selling activity for Crispr Therapeutics.

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRSP stock can currently be purchased for approximately $62.26.

Crispr Therapeutics has a market capitalization of $3.80 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.

The official website for Crispr Therapeutics is www.crisprtx.com.

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]